Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:FHTX NASDAQ:IVA NASDAQ:JANX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.35+2.1%$4.39$3.04▼$5.10$841.51M0.631.39 million shs1.73 million shsFHTXFoghorn Therapeutics$3.64+0.3%$4.59$3.27▼$6.95$213.13M2.89164,175 shs144,266 shsIVAInventiva$4.04-1.2%$5.32$2.85▼$7.98$849.52M0.68342,124 shs1.25 million shsJANXJanux Therapeutics$13.59-1.4%$14.51$12.12▼$35.34$840.36M2.53928,122 shs688,788 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma-4.91%-8.19%-1.39%-10.32%+26.79%FHTXFoghorn Therapeutics-8.56%-16.93%-23.74%-35.98%-12.95%IVAInventiva-14.26%-20.74%-17.95%-32.06%+20.65%JANXJanux Therapeutics-4.37%-4.31%-3.91%-3.97%-44.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.35+2.1%$4.39$3.04▼$5.10$841.51M0.631.39 million shs1.73 million shsFHTXFoghorn Therapeutics$3.64+0.3%$4.59$3.27▼$6.95$213.13M2.89164,175 shs144,266 shsIVAInventiva$4.04-1.2%$5.32$2.85▼$7.98$849.52M0.68342,124 shs1.25 million shsJANXJanux Therapeutics$13.59-1.4%$14.51$12.12▼$35.34$840.36M2.53928,122 shs688,788 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma-4.91%-8.19%-1.39%-10.32%+26.79%FHTXFoghorn Therapeutics-8.56%-16.93%-23.74%-35.98%-12.95%IVAInventiva-14.26%-20.74%-17.95%-32.06%+20.65%JANXJanux Therapeutics-4.37%-4.31%-3.91%-3.97%-44.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 2.00Hold$5.0014.94% UpsideFHTXFoghorn Therapeutics 2.88Moderate Buy$11.43213.97% UpsideIVAInventiva 3.10Buy$16.56309.79% UpsideJANXJanux Therapeutics 2.60Moderate Buy$45.85237.35% UpsideCurrent Analyst Ratings BreakdownLatest FHTX, IVA, ABUS, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026JANXJanux Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$22.005/8/2026JANXJanux Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $26.005/8/2026JANXJanux Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$45.00 ➝ $36.005/8/2026JANXJanux Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$68.00 ➝ $58.005/4/2026JANXJanux Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/28/2026JANXJanux Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $28.004/22/2026JANXJanux Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026FHTXFoghorn Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026IVAInventiva Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ABUSArbutus Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026JANXJanux Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Underweight$29.00 ➝ $14.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$14.08M61.03N/AN/A$0.40 per share10.88FHTXFoghorn Therapeutics$30.91M6.91N/AN/A($1.92) per share-1.90IVAInventiva$5.07M165.51N/AN/A($0.22) per share-18.36JANXJanux Therapeutics$13.73M60.35N/AN/A$15.91 per share0.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$33.50M$0.835.24N/AN/A83.95%129.32%112.24%8/5/2026 (Estimated)FHTXFoghorn Therapeutics-$74.28M-$1.16N/AN/AN/A-266.88%N/A-35.38%8/4/2026 (Estimated)IVAInventiva-$400.67MN/AN/AN/AN/AN/AN/AN/AN/AJANXJanux Therapeutics-$113.62M-$1.84N/AN/AN/AN/A-12.93%-12.23%8/6/2026 (Estimated)Latest FHTX, IVA, ABUS, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ABUSArbutus Biopharma-$0.03$0.87+$0.90$0.87$0.75 million$179.13 million5/7/2026Q1 2026FHTXFoghorn Therapeutics-$0.28-$0.29-$0.01-$0.29$7.94 million$3.27 million5/7/2026Q1 2026JANXJanux Therapeutics-$0.5202-$0.39+$0.1302-$0.39$4.36 million$3.73 million3/31/2026Q4 2025ABUSArbutus BiopharmaN/A$0.87N/A$0.87N/A$179.13 million3/30/2026Q4 2025IVAInventiva-$0.18-$0.7480-$0.5680-$0.16$8.67 million$0.01 million3/20/2026Q4 2025ABUSArbutus Biopharma-$0.0550-$0.01+$0.0450-$0.01$0.83 million$1.05 million3/11/2026Q4 2025FHTXFoghorn Therapeutics-$0.30-$0.34-$0.04-$0.34$9.50 million$9.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A54.2654.26FHTXFoghorn TherapeuticsN/A2.922.92IVAInventivaN/A3.163.16JANXJanux TherapeuticsN/A17.0117.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%FHTXFoghorn Therapeutics61.55%IVAInventiva19.06%JANXJanux Therapeutics75.39%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma19.90%FHTXFoghorn Therapeutics7.58%IVAInventiva32.00%JANXJanux Therapeutics7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90197.54 million158.23 millionOptionableFHTXFoghorn Therapeutics12058.71 million54.26 millionOptionableIVAInventiva100207.71 million141.24 millionNot OptionableJANXJanux Therapeutics3060.98 million56.17 millionOptionableFHTX, IVA, ABUS, and JANX HeadlinesRecent News About These CompaniesWall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should KnowMay 28, 2026 | zacks.comHere's Why You Should Add JANX Stock to Your Portfolio NowMay 26, 2026 | zacks.comJanux Therapeutics (JANX) price target decreased by 14.60% to 42.12May 14, 2026 | msn.comWedbush Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)May 14, 2026 | theglobeandmail.comJanux Therapeutics (NASDAQ:JANX) VP Sells $28,878.46 in StockMay 13, 2026 | marketbeat.comLifesci Capital Comments on JANX Q2 EarningsMay 11, 2026 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Price Target Lowered to $26.00 at Piper SandlerMay 8, 2026 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Price Target Cut to $36.00 by Analysts at WedbushMay 8, 2026 | marketbeat.comGuggenheim Cuts Janux Therapeutics (NASDAQ:JANX) Price Target to $58.00May 8, 2026 | marketbeat.comJanux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue EstimatesMay 7, 2026 | zacks.comHow Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%May 7, 2026 | zacks.comJanux Therapeutics (JANX) Expected to Announce Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Upgraded by Truist Financial to Strong-Buy RatingMay 5, 2026 | marketbeat.comJanux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash ValueMay 4, 2026 | seekingalpha.comPictet Asset Management Holding SA Sells 322,580 Shares of Janux Therapeutics, Inc. $JANXMay 4, 2026 | marketbeat.comJanux Therapeutics halts early stage cancer program in 'prudent' moveApril 28, 2026 | msn.comJANX stock edges up after hours after discontinuing cancer program in favor of remaining pipelineApril 28, 2026 | msn.comJanux Therapeutics Announces Discontinuation of JANX008 Clinical DevelopmentApril 28, 2026 | finance.yahoo.comFirst Patient Dosed in JANX014 Trial in Metastatic CRPCApril 22, 2026 | targetedonc.comTBarclays downgrades Janux Therapeutics (JANX)April 20, 2026 | msn.comFirst patient receives JANX014 dose in Janux’s trial for mCRPCApril 17, 2026 | clinicaltrialsarena.comCNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAs Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 2026AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?By Jessica Mitacek | May 12, 2026Norwegian Cruise Line Cuts Outlook as Headwinds BuildBy Jennifer Ryan Woods | May 5, 2026Old Money, New Tech: Western Union's Crypto RebootBy Jeffrey Neal Johnson | May 6, 2026A Real Biggie Deal: Wendy's Serves Up a Juicy Buyout ArbitrageBy Jeffrey Neal Johnson | May 13, 2026FHTX, IVA, ABUS, and JANX Company DescriptionsArbutus Biopharma NASDAQ:ABUS$4.35 +0.09 (+2.11%) Closing price 04:00 PM EasternExtended Trading$4.34 0.00 (-0.11%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Foghorn Therapeutics NASDAQ:FHTX$3.64 +0.01 (+0.28%) Closing price 04:00 PM EasternExtended Trading$3.70 +0.06 (+1.62%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Inventiva NASDAQ:IVA$4.04 -0.05 (-1.22%) Closing price 04:00 PM EasternExtended Trading$4.03 -0.01 (-0.22%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Janux Therapeutics NASDAQ:JANX$13.59 -0.19 (-1.38%) Closing price 04:00 PM EasternExtended Trading$13.77 +0.18 (+1.35%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coke's $10B India IPO Plan Pops the Top on Hidden Value Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test FedEx Unboxes Billions in Post-Spinoff Value Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
